SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0648+8.0%3:24 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Jack Russell11/21/2013 8:13:37 PM
1 Recommendation

Recommended By
Howard Williams

   of 13111
 
November 21, 2013

PV-10 continues to show robust effect in cutaneous Stage III-IV melanoma

An article appearing the November/December 2013 issue of Oncology News reports on the final analysis of PV-10 Phase 2 melanoma study data presented at the European Cancer Congress 2013 meeting, finding both the number of lesions injected and presence of blistering to be prognostic for outcome.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News